Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.
北卡罗来纳州达勒姆，2024年4月24日（GLOBE NEWSWIRE）——以开发有效改善和延长面临致命疾病的患者寿命的药物为使命的生物制药公司Chimerix（纳斯达克股票代码：CMRX）今天宣布，它将在美国东部时间2024年5月1日星期三上午8点30分举办电话会议和网络音频直播，公布截至3月31日的第一季度财务业绩，2024 年，并提供业务概览。
To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
要观看电话会议，请在开始时间前至少五分钟拨打（646）307-1963（国内）或（800）715-9871（国际），并参考会议编号1246220。本次电话会议的网络直播也将在公司网站的投资者专区播出， www.chimerix.com。活动结束大约两小时后，Chimerix网站上将提供存档的网络直播。
About Chimerix
关于 Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Chimerix是一家生物制药公司，其使命是开发能够有效改善和延长面临致命疾病的患者寿命的药物。该公司最先进的临床阶段开发项目 ONC201 正在开发针对 H3 k27M 突变神经胶质瘤。
CONTACT:
Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com
联系人：
威尔·奥康纳
斯特恩投资者关系
212-362-1200
will@sternir.com
Source: Chimerix, Inc.
来源：Chimerix, Inc.